Literature DB >> 25931232

Risk of thiamine deficiency and Wernicke's encephalopathy after gastrointestinal surgery for cancer.

Angelo Restivo1, Mauro Giovanni Carta2, Anna Maria Giulia Farci3, Laura Saiu3, Gian Luigi Gessa4,5, Roberta Agabio5.   

Abstract

BACKGROUND: Cancer patients submitted to gastrointestinal surgery are at risk of thiamine deficiency (TD) and Wernicke's encephalopathy (WE). Although permanent neurological damage and death could be prevented by a timely replacement therapy, they often remain undiagnosed and untreated. We hypothesized that WE remains unrecognized because most cases may manifest several months after hospital discharge.
METHODS: WE frequency was investigated in a sample of cancer patients who underwent gastrointestinal surgery, by using the diagnostic criteria proposed to improve diagnosis among alcoholics. Patients were evaluated at discharge through the examination of medical records and 6 months after by telephonic interview.
RESULTS: Forty-five patients were selected. Signs of WE resulted in 4.4% at discharge. At 6 months, 21 patients were interviewed. Among them, 90.4% had signs of WE. The number of affected patients was significantly higher 6 months after discharge than at discharge (90.4 vs 9.5%, p < 0.0001).
CONCLUSIONS: Further studies with larger samples are needed to establish the prevalence of TD and related WE in cancer patients after gastrointestinal surgery. This study suggests that the problem is understated. Even in absence of symptoms of TD, the use of prophylactic thiamine supplementation should be taken in consideration, as consequences of misdiagnosis can be severe.

Entities:  

Keywords:  Colorectal cancer; Gastrointestinal cancer; Thiamine deficiency therapy; Wernicke’s encephalopathy prevention

Mesh:

Substances:

Year:  2015        PMID: 25931232     DOI: 10.1007/s00520-015-2748-z

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  32 in total

1.  [Changes in nerve excitability & conductibility induced by novocaine combined with thiamine].

Authors:  G MESSINA
Journal:  Boll Soc Ital Biol Sper       Date:  1956 Oct-Nov

Review 2.  Myths and misconceptions of Wernicke's encephalopathy: what every emergency physician should know.

Authors:  Michael W Donnino; Jose Vega; Joseph Miller; Mark Walsh
Journal:  Ann Emerg Med       Date:  2007-08-03       Impact factor: 5.721

Review 3.  Wernicke encephalopathy after bariatric surgery: a systematic review.

Authors:  Erlend Tuseth Aasheim
Journal:  Ann Surg       Date:  2008-11       Impact factor: 12.969

4.  What goes around comes around? Wernicke encephalopathy and the nationwide shortage of intravenous multivitamins revisited.

Authors:  Ross Perko; Julie H Harreld; Kathleen J Helton; Noah D Sabin; Cyrine E Haidar; Karen D Wright
Journal:  J Clin Oncol       Date:  2012-09-24       Impact factor: 44.544

5.  An unlikely culprit--the many guises of thiamine deficiency.

Authors:  Ami Schattner; Asaf Kedar
Journal:  Am J Emerg Med       Date:  2013-02-04       Impact factor: 2.469

Review 6.  Thiamine supplementation in the critically ill.

Authors:  William Manzanares; Gil Hardy
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2011-11       Impact factor: 4.294

7.  Two cases of thiamine deficiency-induced lactic acidosis during total parenteral nutrition.

Authors:  K Kitamura; T Takahashi; H Tanaka; M Shimotsuma; A Hagiwara; T Yamaguchi; S Hashimoto
Journal:  Tohoku J Exp Med       Date:  1993-10       Impact factor: 1.848

8.  Development of Wernicke-Korsakoff syndrome after long intervals following gastrectomy.

Authors:  T Shimomura; E Mori; N Hirono; T Imamura; H Yamashita
Journal:  Arch Neurol       Date:  1998-09

9.  Wernicke's encephalopathy: an underrecognized and reversible cause of confusional state in cancer patients.

Authors:  Sheng-Han Kuo; J Mathew Debnam; Gregory N Fuller; John de Groot
Journal:  Oncology       Date:  2008-11-19       Impact factor: 2.935

10.  Wernicke-korsakoff syndrome in primary peritoneal cancer.

Authors:  Ki Hyang Kim
Journal:  Case Rep Oncol       Date:  2013-12-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.